May 17, 2012
For patients with multiple myeloma, bisphosphonate treatment is associated with reduced pathological vertebral fractures, skeletal related events (SREs), and pain, but bisphosphonates do not appear to improve overall survival (OS), with the exception of zoledronate, which has been found to be superior to placebo and etidronate for improving OS.